Business Wire

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings

Share

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2.

The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-risk profile for Iclusig in patients with CP-CML is achieved with a daily starting dose of 45 mg followed by a dose reduction to 15 mg upon achieving ≤1% BCR-ABL1. This dosing regimen resulted in an adjudicated arterial occlusive event (AOE) rate of 5.3%.

“As a physician, my focus is on treating CP-CML patients in a manner that will provide the best possible outcome by achieving desirable efficacy, while maintaining a manageable safety profile,” said Dr. Gianantonio Rosti, M.D., Institute of Haematology and Oncology, St Orsola University Hospital, Bologne. “I believe that patient selection, good management of comorbidities, close monitoring and appropriate dose adjustments are key factors in the management of CP-CML. I am encouraged by these data on the benefit-risk profile that is emerging from the interim OPTIC data of the Iclusig regimen starting at 45 mg, followed by a dose reduction to 15 mg.”

“The interim data from OPTIC provide important additional context around the safety profile of Iclusig in appropriate patients with CP-CML.” said Luca Marini, M.D., Regional VP, Head of European Medical Affairs, Incyte. “We believe that they may offer additional guidance to healthcare providers on how to optimize treatment with the goal of maintaining efficacy while reducing the risk of arterial occlusive events.”

Key findings from the OPTIC interim analysis (IA; cutoff date of July 2019) include:

  • With median follow-up time of approximately 21 months, 77% (n/N=216/282) of patients in the OPTIC trial were evaluable for the primary endpoint.
  • The OPTIC IA shows benefit of ponatinib in all three starting doses in a largely resistant population where the majority of patients (>60%) demonstrated less than a complete hematologic response (CHR) to immediate prior therapy.
  • The maximum rates of ≤1% BCR-ABL1IS at 12 months were achieved in the 45 mg/day starting dose cohort (38.7%), and responses were maintained with the dose reduction to 15 mg/day.
  • With the protocol-mandated dose reduction for response in the higher dose cohorts, 75% patients in 45 mg cohort and 88% patients in 30 mg cohort were able to maintain ≤1% BCR-ABL1IS response for as long as up to two years.
  • Safety data as of the IA cutoff date include:
    • Among all patients (N=282), the most common treatment-emergent adverse events (TEAEs) of any grade (occurring in ≥10% of all patients) were thrombocytopenia (39.4%), neutropenia (25.2%), hypertension (24.1%), anemia (17.4%), headache (17.0%), increased lipase (16.0%), arthralgia (14.2%), constipation (12.4%), platelet count decrease (10.6%) and ALT increase (10.3%).
    • There was a dose-dependent trend in arterial occlusive event (AOE) rates:
      • Pre-adjudicated AOEs were reported in (45 mg, 30 mg, 15 mg/day starting dose cohorts) 8.5% (n/N = 8/94), 4.3% (n/N = 4/94), and 2.1% (n/N = 2/94).
      • Prospective adjudication of AOEs by independent experts resulted in (45 mg, 30 mg, 15 mg/day starting dose cohorts) 5.3% (n/N = 5/94), 4.3% (n/N = 4/94), and 1.1% (n/N = 1/94).
    • At the IA, there were no AOE-related deaths reported.
  • The complete primary analysis of the OPTIC trial will be conducted after all patients have at least 12 months of follow-up and will be presented at a later date.

Incyte has an exclusive license from Takeda Pharmaceuticals International AG to commercialize Iclusig in the European Union and 29 other countries, including Switzerland, UK, Norway, Turkey, Israel and Russia. Iclusig is marketed by Takeda Pharmaceuticals International AG in the U.S.

About the OPTIC Trial

OPTIC (Optimizing Ponatinib Treatment In CML) is a randomized, dose-ranging Phase 2 trial designed to evaluate three starting doses (15 mg, 30 mg, 45 mg) of Iclusig® (ponatinib) in patients with resistant chronic-phase chronic myeloid leukemia (CP-CML) or who had documented history of presence of T315I mutation after receiving any number of prior tyrosine kinase inhibitors (TKIs). Dose reduction at response occurred per study protocol. The trial is expected to inform the optimal use of Iclusig in these patients. The primary endpoint of the trial is achieving ≤1% BCR-ABL1 at 12 months. Approximately 283 patients were enrolled at clinical sites around the world. Dose reduction at response occurred per study protocol.

For more information about the OPTIC study, please visit: https://clinicaltrials.gov/ct2/show/NCT02467270.

About CML and Ph+ ALL

CML – a rare malignancy – is one of four main types of leukemia; it is a result of a genetic mutation that takes place in early, immature versions of myeloid cells, which form red blood cells, platelets and most types of white blood cells. Subsequently, an abnormal gene called BCR-ABL1 forms, turning the damaged cell into a CML cell. CML typically progresses slowly, but it can change into a fast-growing acute leukemia that is hard to treat.

Ph+ ALL is a rare form of ALL that accounts for one quarter of adult ALL cases. and is characterized by the presence of an abnormal gene, known as the Philadelphia chromosome. In patients who are Philadelphia chromosome positive (Ph+), an abnormal chromosome is formed when pieces of chromosomes 9 and 22 switch with each other. This forms a longer chromosome 9 and a shorter chromosome 22, which leads to the development of BCR-ABL1 and is associated with Ph+ ALL.

About Iclusig® (ponatinib) Tablets

Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs.

Iclusig is approved in the U.S., EU, UK, Australia, Switzerland, Israel and Canada.

In the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

Click here to view the Iclusig EU Summary of Medicinal Product Characteristics.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the OPTIC trial, and whether or when ponatinib might be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO and EHA meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended March 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.

References

  1. Cortes, J. Interim Analysis (IA) of OPTIC: A Dose-Ranging Study of Three Ponatinib (PON) Starting Doses. Abstract #7502. 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31, 2020).
  2. Cortes, J. Interim Analysis from the OPTIC Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib. Abstract #S172. 25th Congress of the European Hematology Association (EHA25; June 11 – 14, 2020).

Contact information

Media

Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Ela Zawislak
+41 795854316
EZawislak@incyte.com

Investors

Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Emirates Mars Mission Announces the Live Stream Link to the Launch of the "Hope Probe"13.7.2020 22:55:00 CESTPress release

The Emirates Mars Mission has announced the link to watch the live streaming of the launch of the "Hope Probe", starting at midnight UAE Time [20:00 GMT] on Tuesday 14 July, on www.emm.ae/live This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005675/en/ The Hope Probe (Photo: AETOSWire) The link provides an opportunity for everyone to witness this historic event, which is the first interplanetary mission from the Arab World. The probe is being launched from the Tanegashima Space Center in Japan at 00:51:27 UAE Time on 15 July [20:51 GMT on 14July], marking an important milestone as part of the promising Emirati project to explore the Red Planet. The launch is the culmination of efforts of a large team of young Emirati cadres, comprising 200 engineers, experts and researchers, who over the past six years have prepared for this moment and ensured that all scientific and logistical preparations to control the Probe mission w

Ergomotion is Prepared for the Accelerated Growth Surge in the Adjustable Bed Base Category13.7.2020 22:29:00 CESTPress release

Ergomotion, the largest manufacturer of adjustable bases worldwide, is prepared for the accelerated growth in the furniture and mattress industry. As the rest of the world was dealing with the expanding pandemic, Ergomotion was learning from their parent company Keeson Technology, in China. Located in the first country to experience COVID-19, Keeson was uniquely positioned to provide valuable insight to how partners and consumers would react to the unexpected crisis in other parts of the world. Additionally, they were able to re-open quickly following the extended Chinese New Year holiday which limited supply disruptions. “Treating our customers as partners and looking at our shared business from their perspective has been a focus of Ergomotion’s in a time where uncertainty is prevalent,” says Johnny Griggs, Chief Operating Officer at Ergomotion. The Ergomotion team is preparedto build on current relationships within the industry and provide support through the pandemic with a better u

Bentley Systems’ Acceleration Fund Announces Launch of The Cohesive Companies, Advancing Infrastructure Digital Twins to Improve Asset Performance13.7.2020 16:01:00 CESTPress release

Bentley Systems, Incorporated, a leading global provider of comprehensive software and digital twins services for advancing the design, construction, and operations of infrastructure, today announced that its Acceleration Fund has launched The Cohesive Companies, a wholly owned subsidiary, anchored by the acquisition of Atlanta-based Cohesive Solutions. The new business venture will include the services team from Bentley’s AssetWise business and the offerings of Bentley, Cohesive, and IBM’s Maximo to support the digital transformation of infrastructure owner-operators. The Cohesive Companies will act as a digital integrator to help infrastructure asset owners upgrade their enterprise environments to leverage digital twins—digital representations and simulations of a physical asset, synchronizing digital context (current existing conditions), digital components (engineering content), and digital chronology (lifecycle change management). Infrastructure digital twins can empower asset ope

Project Management Institute Announces List of 50 Next Generation Leaders to Watch13.7.2020 15:00:00 CESTPress release

Project Management Institute (PMI) today announced its first annual Future 50 list, which features the 50 next generation leaders that are creating, building, and transforming the world through notable projects. The 50 young standout project leaders highlighted in the specially dedicated July/August issue of https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.pmnetwork-digital.com%2Fpmnetwork%2Fjuly_august_2020&esheet=52248039&newsitemid=20200713005075&lan=en-US&anchor=PM+Network%26%23174%3B+magazine&index=1&md5=b87a3fa432ccbcdd2816b3ede58c905c PM Network® magazine represent the wave of change and talent around the globe—a youthquake that will reshape the future and accelerate innovation in the here and now. Honorees include groundbreaking achievements from people across a variety of industries and countries, including Director Greta Gerwig, Laura Jones from the Special Olympics and Miishe Addy from Jetstream Africa. This press release features multimedia. View the fu

Become a Pet Trainer in the Newest Mabinogi “P.E.T.” Update Arriving on July 1613.7.2020 15:00:00 CESTPress release

Mabinogi,Nexon’s free-to-play fantasy MMORPG will be receiving the delightful new “P.E.T.” update on July 16! Following the introduction of Mabinogi’s exciting furry pets in the “My Little Pet” update, the World of Erinn is changing with the addition of more powerful Fynn Pets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005083/en/ Mabinogi P.E.T. (Graphic: Business Wire) While the recent “My Little Pet” update expanded activities for pets embarking on expeditions to explore the world of Erinn, the P.E.T. update challenges players with a new Pet Training talent to discover the Power of the Fynn and set out to unlock stronger Fynn Pets. To unlock Fynn Pets, players need to sync their main pet with other pets using Fynn Sync. The Fynn Pet will receive the Power of the Fynn, increasing a pet’s max level, inventory, summoning time and more! With the update, players can also defeat monsters to obtain Fynni Gems and bloom

Rimini Street Appoints Gerard Brossard as COO13.7.2020 15:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced the appointment of Gerard Brossard to the newly created role of executive vice president and chief operating officer (COO). Brossard is responsible for Rimini Street’s global field operations and the global sales and success of the Company’s Support and Application Management Services for Oracle and SAP products. Brossard reports directly to Rimini Street CEO, Seth A. Ravin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005192/en/ Rimini Street Appoints Gerard Brossard as COO (Photo: Business Wire) New COO Brings Proven Capabilities to Support Accelerating Company Growth Prior to joining Rimini Street, Brossard served as executive vice president and general manager of Rackspace’s Global Solutions and S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom